EuroNeut41: Safety & Immunogenicity of Immunisations With HIV Vaccine
NCT ID: NCT01509144
Last Updated: 2014-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2012-01-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To assess the safety of three priming immunisations by nasal route followed by two booster immunisations by intramuscular route
* To assess immunogenicity responses induced by the vaccine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine
NCT01827397
Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection
NCT00001386
Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant
NCT01473810
HIV Vaccine Study in HIV Positive Patients
NCT01071031
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
NCT01218113
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nasal active low dose + IM active
Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
nasal active mid dose + IM active
Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
nasal active full dose + IM active
Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
nasal placebo + IM active
Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
nasal placebo + IM placebo
Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
Na Cl Placebo vaccine
Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EN41-FPA2 HIV vaccine
Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
Na Cl Placebo vaccine
Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Available for a maximal study duration of 12/13 months from the inclusion
3. Willing and able to give written informed consent
4. At low risk of HIV infection and willing to remain so for the duration of the study defined as:
* no history of injecting drug use in the previous ten years
* no gonorrhoea or syphilis in the last six months
* no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months
* no unprotected anal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative
* no unprotected vaginal intercourse in the last six months outside a relationship with a regular known HIV negative partner
* not had unprotected sex with someone from a region where HIV is more common (e.g Sub-Saharan African, Caribbean, South East Asia) outside a relationship with a regular known HIV negative partner
5. Negative HIV 1/2 antibody/antigen test at screening
6. If heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; use of condoms incorporating spermicide if using these; physiological or anatomical sterility) from 14 days prior to the first vaccination until 6 months after the last, and willing to undergo urine pregnancy tests prior to each vaccination and blood pregnancy test at screening and final follow up.
7. Agree, to abstain from medications or other agents that are applied via the nasal route from 24 hours prior to each nasal vaccine dosing through to the safety assessment 1week later
8. Agree to abstain from donating blood during their participation in the trial
9. Registered with GP and medical history available for 12 months before dosing
10. Satisfactory response received from General Practitioner relating to medical history before randomization.
Exclusion Criteria
2. Positive alcohol test
3. Positive drugs of abuse test
4. Clinically relevant abnormality on history or examination:
* central nervous system disorder or disease, including
* history of grand-mal epilepsy
* cranial nerve palsies
* severe eczema
* severe epistaxis requiring surgical intervention or blood transfusion
* clinically significant liver disease
* clinically significant haematological, metabolic, gastrointestinal, renal, psychiatric or cardio-pulmonary disorders
* ongoing infection;
* autoimmune disease, immunodeficiency or use of immunosuppressive agents in preceding 3 months prior to dosing
* using inhaled cortico-steroids and intranasal medications
5. Known or suspected history of clinically relevant nasal surgery, injury, nasal polyps or cleft palate, or a condition likely to require regular intranasal medication, which in the opinion of the investigator might interfere with intranasal vaccine administration
6. Known hypersensitivity to any component of the vaccine formulations used in this trial or have severe or multiple allergies
7. History of severe local or general reaction to vaccination defined as
* local: extensive, indurated redness and swelling involving most of the antero-lateral thigh or the major circumference of the arm, not resolving within 72 hours
* general: fever \> 39.5°C within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
8. Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of scheduled study vaccine dosing
9. Receipt of an experimental vaccine containing HIV envelope proteins at any time in the past
10. Receipt of blood products or immunoglobin within 4 months of screening
11. Participation in another trial of a medicinal product, completed less than 90 days prior to Visit 2 and planned participation in another clinical trial during the present trial
12. HIV 1/2 antibody/antigen positive or indeterminate on screening
13. Positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment
14. Clinically significant routine laboratory parameters.
15. Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.
16. Unlikely to comply with protocol
17. History of drug or alcohol abuse or regular using of drugs, or who test positive in drugs of abuse and alcohol test at screening or admission
18. Has a condition, or is on regular medication (other than paracetamol, multivitamin, E45, or over the counter remedies) which in the opinion of the investigator is not suitable for participation in the study
19. Any local vaginal, cervical or gynaecological condition which may interfere with collection or interpretation of data collected through vaginal samples.
20. Using any Intra Uterine Contraceptive Device; as there is a risk of dislodging, displacing or removing the device when pulling or removing Softcup used for vaginal sampling.
21. Clinically significant abnormality on ECG performed at the screening visit
22. Any condition that, in the investigator's opinion, compromises the volunteer's ability to meet protocol requirements or to complete the study.
18 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Commission
OTHER
PX'Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Surrey Clinical Research Centre University of Surrey
Guildford, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-023693-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.